HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bendheim, P. E. Articles by Berg, B. O. Search for Related Content PubMed PubMed Citation Articles by Bendheim, P. E. Articles by Berg, B. O.

ß-Adrenergic treatment of hyperkalemic periodic paralysis

Departments of Neurology (Drs. Bendheim and Berg) and Pediatrics (Dr. Berg), and the Division of Clinical Pharmacy (Dr. Reale), University of California, San Francisco, CA.

In a patient with hyperkalemic periodic paralysis, metaproterenol prevented muscular weakness and hyperkalemia in periods of rest after exercise. During a severe attack, the drug rapidly corrected hyperkalemia and seemed to enhance the return of strength. The action of metaproterenol may involve a ß-adrenergic-mediated increase of potassium transport via the sodium-potassium pump.

Address correspondence and reprint requests to Dr. Bendheim, Department of Pathological Neurobiology, Institute for Basic Research, 1050 Forest Hill Rd., Staten Island, NY 10314.

Accepted for publication September 12, 1984.

This article has been cited by other articles:

				M G Hanna, J Stewart, A H V Schapira, N W Wood, J A Morgan-Hughes, and N M F Murray Salbutamol treatment in a patient with hyperkalaemic periodic paralysis due to a mutation in the skeletal muscle sodium channel gene (SCN4A) J. Neurol. Neurosurg. Psychiatry, August 1, 1998; 65(2): 248 - 250. [Abstract] [Full Text]